Similar articles

• Prolactin lowering effect of dihydroergokryptine in rat and in man.

  Poli M, Cocchi D, Mailland F, Masu AM, Landi G, Craveri A, Müller EE. Poli M, et al. J Endocrinol Invest. 1986 Feb;9(1):31-6. doi: 10.1007/BF03348059. J Endocrinol Invest. 1986. PMID: 3084616 Clinical Trial.
• Measuring the inhibition of TRH-stimulated prolactin by dihydroergocristine (DEC) in man: an indirect assessment of bioavailability.

  Venitz J, Lücker PW, Albrecht H, Mailland F. Venitz J, et al. Methods Find Exp Clin Pharmacol. 1984 Oct;6(10):645-7. Methods Find Exp Clin Pharmacol. 1984. PMID: 6439963
• [Blood prolactin-lowering activity of dihydroergocristine].

  Cocchi D, Müller EE, Boselli P, Faini D. Cocchi D, et al. Farmaco Sci. 1985 Jul;40(7):534-40. Farmaco Sci. 1985. PMID: 3930286 Italian.
• Cimetidine and prolactin: a study with dihydroergocristine.

  Poli M, Caviezel F, Bosi E, Murari M, Bonetti M. Poli M, et al. Horm Metab Res. 1982 Nov;14(11):616-7. doi: 10.1055/s-2007-1019098. Horm Metab Res. 1982. PMID: 6818118 No abstract available.
• Prolactin response to sulpiride in ovulatory women (a clue for the screening of hyperprolactinemic states).

  Nahoum CR, Pantaleão JA, Freire RR, Franco S. Nahoum CR, et al. Int J Fertil. 1984;29(1):20-4. Int J Fertil. 1984. PMID: 6146579